-
$3.5 million per dose! FDA approves Pfizer's one-time gene therapy for hemophilia B
On Friday Eastern Time, US pharmaceutical giant Pfizer announced that the US Food and Drug Administration (FDA) has approved a gene therapy for treating hemophilia, making it the first gene therapy a ... -
Pfizer's new hemophilia treatment drug Mataximab's application for market launch in China has been accepted
On August 13th, the official website of the Drug Evaluation Center (CDE) of the China National Medical Products Administration (NMPA) announced that the Class 1 therapeutic biological product Mataxim ... -
The first weekly long-acting hemophilia therapy has been approved by the FDA from Pfizer
On October 11th local time, the US FDA approved Pfizer's drug Hympavzi (marstalimab) for routine prevention or reduction of bleeding in adult and pediatric patients aged 12 and above with hemophilia ...